Clinical trial · Interventional
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma
NCT00186394CI-TRIAL-00003707completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blood and Marrow Transplant (BMT) | — | UNRESOLVED | — |
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ablative allogeneic hematopoietic cell transplantation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Safety
- measure
- Toxicity
- measure
- Efficacy
Secondary outcomes (1)
- measure
- Incidence of acute and chronic GVHD
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 61 Years
Show eligibility criteria text
Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma Age: \>18 and \<61 years of age Signed informed consent Exclusion Criteria:Hepatic dysfunction defined by serum transaminases \>2.5X normal values Serum creatinine of \> 2 mg/dl or creatinine clearance \< 60 ml/min Diseases other than non-Hodgkin's lymphoma Prior bone marrow transplant procedure Severe psychological or medical illness
References
Publications (0)
Data not yet available
No reference posted for this study.